Ophthalmoplegia Market

Market Overview:

The 7 major ophthalmoplegia markets are expected to exhibit a CAGR of 6.22% during 2024-2034.

The ophthalmoplegia market has been comprehensively analyzed in IMARC's new report titled "Ophthalmoplegia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Ophthalmoplegia is a medical condition characterized by weakness or paralysis of the muscles responsible for eye movements. Depending on the location of the affected muscles, this disease can be categorized as either external or internal. External ophthalmoplegia refers to an impairment of the extraocular muscles, most commonly those that regulate eye motion. Internal ophthalmoplegia, on the other hand, involves the muscles within the eye itself, which are responsible for constriction and the size of the pupil. Individuals suffering from ophthalmoplegia may experience difficulty moving their eyes in certain directions, double vision, droopy eyelids, blurred vision, problems with focusing, etc. The diagnosis of the illness usually requires a comprehensive evaluation of medical history, underlying indications, and a physical examination. The healthcare provider will also perform neurological tests involving the nerves that control eye movements to check for any signs of weakness or abnormal reflexes. Numerous imaging studies, such as magnetic resonance imaging (MRI) and computed tomography (CT) scans, are further required to visualize the structures of the brain, eye sockets, and surrounding tissues.

The increasing cases of head injuries or trauma to the eye structures, which can directly damage the cranial nerves or their pathways, are primarily driving the ophthalmoplegia market. In addition to this, the rising prevalence of autoimmune conditions, like thyroid eye disease, that involve inflammation of the eye muscles or surrounding tissues is also creating a positive outlook for the market. Moreover, the widespread adoption of botulinum toxin injections for treating the ailment on account of their numerous advantages, such as better alignment and reduced double vision, is further bolstering the market growth. Apart from this, the escalating application of immunosuppressive therapy, since it suppresses the body's immune response to control inflammation and prevents the worsening of muscle damage among patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of decompression surgery, which aims to relieve the compression or entrapment of the affected nerves and allow for restoration of eye function, thereby enhancing the quality of life, is expected to drive the ophthalmoplegia market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the ophthalmoplegia market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for ophthalmoplegia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the ophthalmoplegia market in any manner.

Key Highlights:

• The prevalence of ophthalmoplegia is estimated to be approximately 0.32%.
• Ophthalmoplegia is a rare consequence after transsphenoidal hypophysectomy, with an incidence range of 0.3% to 1.4%.
• The primary risk factor for ophthalmoplegia is age ≥ 45 years.
• Ophthalmoplegia is slightly more common among diabetics.
• Ophthalmoplegia mostly affects men compared to women.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the ophthalmoplegia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the ophthalmoplegia market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current ophthalmoplegia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the ophthalmoplegia market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the ophthalmoplegia market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the ophthalmoplegia market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of ophthalmoplegia across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of ophthalmoplegia by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of ophthalmoplegia by gender across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with ophthalmoplegia across the seven major markets?
• What is the size of the ophthalmoplegia patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of ophthalmoplegia?
• What will be the growth rate of patients across the seven major markets?
   

Ophthalmoplegia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for ophthalmoplegia drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the ophthalmoplegia market?
• What are the key regulatory events related to the ophthalmoplegia market?
• What is the structure of clinical trial landscape by status related to the ophthalmoplegia market?
• What is the structure of clinical trial landscape by phase related to the ophthalmoplegia market?
• What is the structure of clinical trial landscape by route of administration related to the ophthalmoplegia market?